Quick Facts

• Supports the management of symptoms associated with digestive disorders in certain animals.
• Contributes to the maintenance of normal hepato-digestive activity.
• Used as a supportive measure in situations involving hepatic imbalance or issues with liver function.

---

What Sodiazot Treats: Main Uses and Benefits

Sodiazot is authorized for veterinary use in select animal populations, including cattle, pigs, dogs, cats, and poultry, primarily to address conditions affecting the liver and digestive system. The principal goal of administration is to assist in the support of normal hepato-digestive activity, which can be impacted by various stresses or underlying conditions.

Specifically, this product may be considered as a supportive element in the management plan for animals experiencing digestive disorders. It is also utilized in cases where there is a presentation of hepatic imbalance, where it is intended to contribute to the maintenance of the liver system. This approach aims to generally support the digestive and hepatic status of the animal. Always confirm appropriate use and indications with a qualified veterinary professional.

Sodiazot is an adjunct component in the veterinary care framework and does not represent a cure for underlying conditions. Its function is to provide supportive elements in the context of broader animal health and well-being.

The eligibility for Sodiazot is defined by its regulatory approval as a veterinary product containing Sorbitol and L-Lysine. Official government documentation establishes specific contraindications and restrictions, limiting use based on patient metabolism and pre-existing conditions.

The medicine is allowed for use in approved species: cattle, pigs, dogs, cats, and poultry.

Regulatory Status	Affected Population or Condition
Contraindicated	Known Hypersensitivity to L-Lysine, Sorbitol, or excipients. Metabolic Exclusions such as Hyperlysinemia or Hereditary Fructose Intolerance must prohibit use.
Not Recommended	Use is generally not recommended during Pregnancy or Lactation due to insufficient reliable safety data for the active components.
Conditional Use	Use requires caution and professional assessment in patients with Renal Impairment, Severe Hepatic Impairment, and in cases of Acute Undiagnosed Abdominal Pain.

Use in the youngest age groups is often subject to specific minimum age or weight thresholds on the authorized label and may be classified as "use not established" until data confirms safety for that population. All restrictions are based strictly on official regulatory classification.

Interactions with other medicines and products

Official regulatory documents define the interaction structure for Sodiazot (Sorbitol and L-Lysine) based on constraints concerning co-administration and pharmacokinetic alterations.

Documented Interaction Constraints

Classification	Interacting Substance	Official Outcome
Contraindicated Combination	Sodium Polystyrene Sulfonate (SPS)	Implicated in severe gastrointestinal injury, including intestinal necrosis; must be avoided.
Exposure-Altering Interaction	Lamivudine Oral Solution	The Sorbitol component causes a dose-dependent reduction in systemic exposure (AUC and Cmax) due to altered absorption and increased gastrointestinal transit time. Chronic co-administration should be avoided.
Pharmacodynamic Risk	Aminoglycoside Antibiotics	Concurrent use may increase the risk of additive nephrotoxicity.
Supplement Interaction	Calcium Supplements	The L-Lysine component is officially documented to enhance the intestinal absorption of calcium.

Population and Contextual Notes

Regulatory reviews indicate that the interaction resulting in reduced Lamivudine exposure is of heightened clinical relevance in the pediatric population. Furthermore, the interaction with Lamivudine is primarily a concern when using the oral solution formulation. The official profile notes a further pharmacodynamic antagonism between the L-Lysine component and the amino acid L-Arginine.

Dual-Action Control of Gastrointestinal Motility and Evacuation

The mechanism relies on a synergistic approach to modulate digestive tract function. Sorbitol provides a non-receptor-mediated osmotic effect in the intestinal lumen, drawing in water to physically increase the bulk and fluid content of the stool. Simultaneously, L-Lysine acts on the Enteric Nervous System (ENS), engaging ion channels (TRPV1) and subsequent cholinergic signaling to directly stimulate the propulsive contraction of gut smooth muscle. This dual activation accelerates transit speed and enhances the physiological process of evacuation.

---

Metabolic Substrate Provision for Hepatic Pathways

Beyond its effects on motility, the L-Lysine component provides substrate to the liver's metabolic pathways. As an amino acid, it contributes to maintaining the integrity and function of key hepatic enzymes, including those involved in the Urea Cycle. This action supports the efficiency of pathways that process and manage nitrogenous waste products (such as ammonia).

How to Use Sodiazot: Official Administration Guidelines

Sodiazot is an oral solution for veterinary use, and its administration must strictly follow the specifications outlined in regulatory prescribing information. The instructions detail the correct route, species-specific dosing, frequency, duration, and preparation requirements.

---

Administration and Dosing

The product is administered exclusively via the oral route. Dosing is standardized based on the animal species and size, corresponding to a core principle of 60 mg of Sorbitol and 1.6 mg of L-Lysine per kilogram of bodyweight daily.

Species/Group	Daily Dose Volume	Dosing Note
Adult Cattle	50 to 80 ml per animal	Administered directly
Young Cattle	30 ml per animal	Administered directly
Poultry	1 to 2 ml per liter of drinking water	Must be diluted in water
Dogs	5 to 15 ml per animal	Administered directly
Cats	2.5 to 5 ml per animal	Administered directly

---

Treatment Schedule

Frequency and Duration

Sodiazot is administered once daily. The official treatment duration is a maximum of 5 days. This set schedule defines the limited time course for the product's supportive use.

Preparation and Conditions

• For Poultry, the required daily dose must be measured and mixed into the animal's drinking water to ensure proper intake.
• For all other species (cattle, pigs, dogs, and cats), the specified volume is administered orally and directly to the animal.

Research evidence / Overview of studies for Sodiazot (Veterinary Use)

---

Evidence for Supportive Hepato-Digestive Management

The research surrounding Sodiazot, which combines Sorbitol and L-Lysine, is primarily focused on research exploring its supportive role in relation to hepatic and digestive function in animals. This evidence base consists mostly of studies on the individual components rather than the specific combination product itself. Research examined use during periods associated with systemic stress or when animals experience outcomes related to systemic or functional imbalance.

Findings largely describe patterns observed in the studies. This evidence remains limited and certainty remains low for the combined product. Studies report changes measured during the study period related to specific liver enzymes and nitrogen metabolism. These findings contribute to the broader evidence landscape by providing context on how these compounds were studied in relation to physiological processes.

Types of Studies and Outcomes Examined

The available evidence is primarily derived from metabolomic and biochemical studies, alongside some controlled trials examining the nutritional impacts of Sorbitol and L-Lysine. Studies monitored outcomes related to physical discomfort and systemic imbalance. Researchers explored structural changes in the liver and intestine and monitored physiological strain markers, such as certain enzyme levels.

A key limitation is that comparative evidence is lacking for the final Sodiazot formulation. Researchers have primarily focused on the metabolic function of each component separately. Consequently, the data show patterns related to Sorbitol's osmotic and stimulant properties, and the observed action of L-Lysine, but they provide less clarity on the specific effects of the Sodiazot formulation.

What Remains Undefined or Uncertain About the Evidence Base

The certainty remains low regarding the full spectrum of effects from the specific Sodiazot combination. The most notable research limitation is the absence of high-quality randomized controlled trials (RCTs) designed specifically to test the clinical efficacy of the Sorbitol and L-Lysine product for its supportive indication. Evidence quality varies across studies, with many relying on small sample sizes and limited follow-up durations.

Common questions about Sodiazot (FAQ)

Q: What is the main purpose of Sodiazot?

According to official veterinary documents, Sodiazot is indicated for the stimulation of hepato-digestive activity. This means the product is used to support digestive function and the liver, particularly during digestive disorders and hepatic insufficiency.

Q: How quickly should I expect Sodiazot to start working?

Official documents do not specify a precise onset time for Sodiazot. The effect of the Sorbitol component is related to fluid dynamics in the intestine. Related veterinary treatments sometimes show initial effects starting within one to two days.

Q: Is it common to feel tired after taking Sodiazot?

Official side effect information for Sodiazot is based on its active components and related veterinary treatments. While tiredness (lethargy, depression, or low energy) is not always a primary side effect, it is sometimes noted in the profiles of similar digestive and hepatic treatments in animals.

Q: Are there any foods or drinks I should avoid while using Sodiazot?

Official regulatory information notes that the L-Lysine component is documented to enhance the intestinal absorption of calcium. This means the product can affect the way calcium is absorbed from the digestive system.

Q: What are the most common side effects listed for Sodiazot?

The official labels for similar veterinary digestive treatments typically describe the most common adverse effects as gastrointestinal signs. These can include events such as diarrhea, vomiting, or a temporary lack of appetite.

Q: Is it normal to feel a mild headache when first starting Sodiazot?

The regulatory documents describing common adverse reactions for similar veterinary digestive treatments focus primarily on gastrointestinal symptoms. Central nervous system effects, such as a headache, are generally not listed in the known side effect profiles for these specific veterinary products.

Q: How is Sodiazot different from a supplement?

Sodiazot is regulated as a veterinary medicine indicated for specific therapeutic uses, such as supporting the liver and digestion during hepatic insufficiency. This is a different regulatory classification than that of an unregulated nutritional supplement.

Q: Are there any specific medical conditions that would prevent me from being eligible for Sodiazot?

Official regulatory documents list specific circumstances that would prevent use, known as contraindications. This includes the concurrent use of Sodium Polystyrene Sulfonate (SPS). The official label may also include warnings against its use in cases of certain severe gastrointestinal or obstructive conditions.

Q: What is the risk of a serious side effect from Sodiazot?

The official label highlights serious risks, particularly those related to drug interactions. These include the potential for severe gastrointestinal injury when used with Sodium Polystyrene Sulfonate, and an increased risk of additive nephrotoxicity (harm to the kidneys) with Aminoglycoside Antibiotics.

Q: Where can I find the official prescribing information for Sodiazot?

The official prescribing information for Sodiazot can be located through the national veterinary medicines regulatory authority (such as ANMV-ANSES in France) or directly from the product manufacturer. These documents contain detailed regulatory information.

Q: Is Sodiazot related to any controlled substances?

The active ingredients in Sodiazot, L-Lysine and Sorbitol, are generally not classified as controlled substances according to standard regulatory scheduling.

Q: Is a metallic taste in the mouth a common side effect of Sodiazot?

Regulatory documents describing common adverse reactions for similar veterinary digestive treatments focus primarily on gastrointestinal symptoms. Effects like a metallic taste in the mouth are generally not specified in the side effect profiles for this type of product.

Q: If I feel better, can I stop taking Sodiazot?

The official administration schedule for Sodiazot defines a maximum treatment duration of five days. This specific schedule sets the defined time course for the product's use.

Q: Is it possible to have an allergic reaction to Sodiazot?

As with virtually all medicines, official regulatory information indicates the potential for a hypersensitivity reaction (an allergic reaction) to any of the active components or non-active ingredients in Sodiazot.

Q: Are there different strengths of Sodiazot available?

The product is generally available as a single oral solution concentration. The dosage, which changes based on the species and weight, is achieved by adjusting the volume of the solution administered, not by changing the concentration of the product itself.

Q: Why is Sodiazot sometimes prescribed with another medicine?

The official mechanisms of Sodiazot—stimulating digestive activity and providing metabolic support for the liver—suggest that it is intended for a supportive role, meaning it can be used alongside other treatments.

The official storage and disposal requirements for the veterinary oral solution Sodiazot (Sorbitol and L-Lysine) are strictly defined to maintain product stability and prevent environmental contamination.

Storage Conditions

Requirement Category	Official Regulatory Statement
Labeled Storage Temperature	Store below 25 C in a cool, dry place.
Light and Moisture Protection	The product must be protected from light and protected from moisture [Source 1].
Packaging Requirements	Keep the solution in its original container and ensure the bottle is tightly closed when not in use [Source 1].

⏳ Stability and Disposal

The product is stable for a defined period when sealed. Once the container is first opened, the shelf-life is limited; any unused portion must be discarded after 3 months [Source 1]. The product must be stored out of the sight and reach of children [Source 1]. Disposal of the solution and all waste materials must be done in accordance with local regulations, with the explicit instruction to not let the product enter drains, surface, or ground water [Source 2].